Entecavir and tenofovir disoproxil fumarate are potent and effective antiviral drugs that now represent recommended treatment options for chronic HBV infection. However, no or very limited clinical evidence is currently available on these drugs for the management of HBV reactivation in patients with haematological malignancies. Herein, we report a case of HBV reactivation in a patient with non-Hodgkin's lymphoma following a rituximab-based regimen, and who was successfully treated with a combination antiviral treatment including entecavir and tenofovir disoproxil fumarate.
References
1.
LauG.K.Hepatitis B reactivation after chemotherapy: two decades of clinical research.Hepatol Int2008; 2: 152–162.
2.
PeiS.N., ChenC.H., LeeC.M.Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients.Ann Hematol2010; 89: 255–262.
3.
TsutsumiY., KanamoriH., MoriA.Reactivation of hepatitis B virus with rituximab.Expert Opin Drug Saf2005; 4: 599–610.
4.
IannittoE., MinardiV., CalvarusoG.Hepatitis B virus reactivation and alentuzumab therapy.Eur J Haematol2005; 74: 254–258.
5.
AksoyS., HarputluogluH., KilckapS.Rituximab related viral infections in lymphoma patients.Leuk Lymphoma2007; 48: 1307–1312.
6.
LalazarG., RundD., ShouvalD.Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies.Br J Haematol2007; 136: 699–712.
7.
LiangR.How I treat and monitor viral hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantation.Blood2009; 113: 3147–3153.
8.
KusumotoS., TanakaY., MizokamiM., UedaR.Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma.Int J Hematol2009; 90: 13–23.
9.
LokA.S., LaiC.L., LeungN.Long-term safety of lamivudine treatment in patients with chronic hepatitis B.Gastroenterology2003; 125: 1714–1722.
10.
FrancisciD., FalcinelliF., SchiaroliE.Management of hepatitis B virus reactivation in patients with haematological malignancies treated with chemotherapy.Infection2010; 38: 58–61.
11.
SvicherV., GoriC., TrignettiM.The profile of mutational clusters associated with lamivudine resistance can be constrained by HBV genotypes.J Hepatol2009; 50: 461–470.
12.
CareyI., HarrisonP.M.Monotherapy versus combination therapy for the treatment of chronic hepatitis B.Expert Opin Investig Drugs2009; 18: 1655–1666.
13.
European Association for the Study of the Liver.EASL Clinical Practice Guidelines: management of chronic hepatitis B.J Hepatol2009; 50: 227–242.
14.
ChangJ.J., LewinS.R.Immunopathogenesis of hepatitis B virus infection.Immunol Cell Biol2007; 85: 16–23.
SozaA., LauD.T., KhokharM.F., ConjeevaramH., ParkY., HoofnagleJ.H.Resolution of chronic hepatitis B-associated autoimmune neutropenia with interferon-alpha therapy.J Pediatr Gastroenterol Nutr2003; 36: 141–143.
17.
ColsonP., BorentainP., CosoD., ChabannonC., TamaletC., GérolamiR.Entecavir as a first-line treatment for HBV reactivation following polychemotherapy for lymphoma.Br J Haematol2008; 143: 148–150.
18.
SanchezM.J., ButiM., HomsM., PalaciosA., Rodriguez-FriasF., EstebanR.Successful use of entecavir for a severe case of reactivation of hepatitis B virus following polychemotherapy containing rituximab.J Hepatol2009; 51: 1091–1096.
